April 9, 2008 — PharmAthene, Inc. (Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced that scientists from the Hebrew University of Jerusalem, one of PharmAthene’s collaboration partners, have recently obtained new data suggesting that recombinant butyrylcholinesterase (rBChE), a non-pegylated form of Protexia®, may have neuroprotective benefits.Recent research conducted by Dr. Hermona Soreq and co-workers at the Alexander Silberman Life Sciences Institute at The Hebrew University of Jerusalem, in collaboration with PharmAthene, examined the role of rBChE in the prevention of amyloid plaques, which are believed to play a role in the development of Alzheimer’s disease... [PDF] PharmAthene's Press Release -
